US EditionFDA warns companies over unapproved weight loss drug sales
5 Articles
5 Articles
FDA warns companies over unapproved weight loss drug sales
The Food and Drug Administration (FDA) said Tuesday in a statement it has sent warning letters to companies selling unapproved weight loss drugs. The letter went to Xcel Peptides, Swisschems, Summit Research and Prime Peptides, four online companies it said were selling unapproved GLP-1 drugs, including semaglutide and tirzepatide. Semaglutide is known for its use…
FDA Warns Online Vendors Selling Unapproved Weight-Loss Drugs
The U.S. Food and Drug Administration said on Tuesday it has sent warning letters to four companies for selling unapproved versions of GLP-1 drugs including semaglutide and tirzepatide, the active ingredients in popular diabetes and weight-loss drugs. The letters were issued to Xcel Peptides, Swisschems, Summit Research, and Prime Peptides last week after the U.S. health regulator conducted a review of their respective websites in October. The w…
US FDA warns online vendors selling unapproved weight-loss drugs
(Reuters) – The U.S. Food and Drug Administration said on Tuesday it has sent warning letters to four companies for selling unapproved versions of GLP-1 drugs including semaglutide and tirzepatide, the active ingredients in popular diabetes and weight-loss drugs. The letters were issued to Xcel Peptides, Swisschems, Summit Research and Prime Peptides last week after the U.S. health regulator conducted a review of their respective websites in…
Educating Patients on Responsible Use of Weight Loss Drugs
The UK’s drug safety regulator is urging healthcare professionals to be vigilant about the misuse of obesity medications, amid growing concerns over patient misuse CREDIT: keep reading The post Educating Patients on Responsible Use of Weight Loss Drugs first appeared on Practice Business.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
